Innate Pharma annonce la présentation de données cliniques sur IPH5401 et monalizumab au congrès de l’ESMO 2019
23 sept. 2019 01h00 HE
|
INNATE PHARMA
INNATE PHARMA ANNONCE LA PRÉSENTATION DE DONNÉES CLINIQUES SUR IPH5401 ET MONALIZUMAB AU CONGRÈS DE L’ESMO 2019 Données préliminaires issues de STELLAR-001, l’étude de Phase I en escalade de dose...
Aravive to Present Late-Breaking Oral Presentation at European Society for Medical Oncology Congress 2019 in Barcelona
18 sept. 2019 08h00 HE
|
Aravive, Inc.
HOUSTON, Sept. 18, 2019 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV) today announced that its late-breaking abstract has been accepted for oral presentation in a proffered paper session at the...
ASLAN Pharmaceuticals to Present New Data on Varlitinib at European Society for Medical Oncology Congress
31 juil. 2019 04h14 HE
|
ASLAN Pharmaceuticals Limited
SINGAPORE, July 31, 2019 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN, TPEx:6497), a clinical-stage oncology and immunology focused biopharma company, today announced that an abstract on...
Helsinn Provides Educational Grant for ESMO’s Preceptorship for Supportive and Palliative Care
31 janv. 2019 03h00 HE
|
Helsinn Healthcare S.A.
Helsinn Provides Educational Grant for ESMO’s Preceptorship for Supportive and Palliative Care Lugano, Switzerland, January 31, 2019 – Helsinn, a Swiss pharmaceutical group focused on...
Updated Data from Ongoing MAGE-A10 and MAGE-A4 Studies Presented at the 2018 ESMO Congress
20 oct. 2018 10h45 HE
|
Adaptimmune Therapeutics plc
PHILADELPHIA and OXFORD, United Kingdom, Oct. 20, 2018 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (“Adaptimmune”) (Nasdaq: ADAP), a leader in T-cell therapy to treat cancer, presented initial...
TESARO Announces Data Presentations at ESMO 2018 Congress
20 oct. 2018 01h30 HE
|
TESARO, Inc.
Data presented indicate that TSR-042 (anti-PD-1 antibody) is well tolerated and has robust activity in patients with MSI-H endometrial cancerPRIMA safety data for individualized niraparib dose regimen...
NANOBIOTIX : Résultats positifs de la Phase II/III dans les Sarcomes des Tissus Mous avec NBTXR3 présentés à l’ESMO
19 oct. 2018 12h05 HE
|
NANOBIOTIX
NANOBIOTIX : RESULTATS POSITIFS DE LA PHASE II/III DANS LES SARCOMES DES TISSUS MOUS AVEC NBTXR3 PRESENTES A L’ESMO Dr. Sylvie Bonvalot, Chef du Service Sarcomes et Tumeurs Complexes de...
NANOBIOTIX: Positive phase II/III results for NBTXR3 in Soft Tissue Sarcoma presented at ESMO
19 oct. 2018 12h05 HE
|
NANOBIOTIX
NANOBIOTIX: POSITIVE PHASE II/III RESULTS FOR NBTXR3 IN SOFT TISSUE SARCOMA PRESENTED AT ESMO Dr. Sylvie Bonvalot, Head of Sarcoma and Complex Tumor Surgery Unit at Institut Curie - Paris,...
ASLAN Pharmaceuticals to Present Posters on Varlitinib and ASLAN003 at European Society for Medical Oncology Congress
09 oct. 2018 06h15 HE
|
ASLAN Pharmaceuticals Limited
SINGAPORE, Oct. 09, 2018 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (ASLAN, 6497.TT, Nasdaq: ASLN), a clinical-stage biopharmaceutical company targeting cancers that are both highly prevalent in Asia...
Data Updates from Ongoing MAGE-A10 Studies and MAGE-A4 Study to be presented at the European Society for Medical Oncology (ESMO) 2018 Congress
08 oct. 2018 18h10 HE
|
Adaptimmune Therapeutics plc
PHILADELPHIA and OXFORD, United Kingdom, Oct. 08, 2018 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (“Adaptimmune”) (Nasdaq: ADAP), a leader in T-cell therapy to treat cancer, today announced...